TGTX Q3 2019 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000+0.0% YoY

Gross Profit

$38,000100.0% margin

Operating Income

-$61M-160160.5% margin

Net Income

-$62M-162973.7% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$93M

Total Liabilities

$119M

Stockholders' Equity

-$662M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$38,000	+0.0%
Gross Profit	$38,000	$38,000	+0.0%
Operating Income	-$61M	-$34M	-77.3%
Net Income	-$62M	-$34M	-82.4%